EMERGENT BIOSOLUTIONS INC. Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax
EMERGENT BIOSOLUTIONS INC. (EBS) reported Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax of $81.50 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-02-22
- EMERGENT BIOSOLUTIONS INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2018 was $81.50M, a 31.28% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2017 was $118.60M, a 19.56% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2016 was $99.20M, a 26.91% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. income (loss), including portion attributable to noncontrolling interest, before tax for fiscal 2015 was $135.72M, a 61.19% increase from fiscal 2014.
| Period end | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month | Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax 12 month as first filed |
|---|---|---|
| 2018-12-31 | $81.50M 10-K · filed 2019-02-22 | |
| 2017-12-31 | $118.60M 10-K · filed 2019-02-22 | $118.63M 10-K · filed 2018-02-23 |
| 2016-12-31 | $99.20M 10-K · filed 2019-02-22 | $99.22M 10-K · filed 2017-02-28 |
| 2015-12-31 | $135.72M 10-K · filed 2018-02-23 | $89.77M 10-K · filed 2016-02-29 |
| 2014-12-31 | $84.19M 10-K · filed 2017-02-28 | $53.06M 10-K · filed 2015-03-09 |
| 2013-12-31 | $44.24M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $37.45M 10-K · filed 2015-03-09 | |
| 2011-12-31 | $38.85M 10-K · filed 2014-03-10 | |
| 2010-12-31 | $77.88M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |